Trial · NCT02357420
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Weekly Vomiting Episodes | Placebo | Baseline | 5.7 | Standard Deviation 6.0 | vomiting episodes per week |
| Change From Baseline to Week 12 in Weekly Vomiting Episodes | Relamorelin 10 μg | Baseline | 7.7 | Standard Deviation 17.2 | vomiting episodes per week |
| Change From Baseline to Week 12 in Weekly Vomiting Episodes | Relamorelin 30 μg | Baseline | 6.9 | Standard Deviation 10.3 | vomiting episodes per week |
| Change From Baseline to Week 12 in Weekly Vomiting Episodes | Relamorelin 100 μg | Baseline | 4.8 | Standard Deviation 5.2 | vomiting episodes per week |
| Change From Baseline to Week 12 in Weekly Vomiting Episodes | Placebo | Change from Baseline to Week 12 | -2.9 | Standard Deviation 5.8 | vomiting episodes per week |
| Change From Baseline to Week 12 in Weekly Vomiting Episodes | Relamorelin 10 μg | Change from Baseline to Week 12 | -3.7 | Standard Deviation 12.5 | vomiting episodes per week |
| Change From Baseline to Week 12 in Weekly Vomiting Episodes | Relamorelin 30 μg | Change from Baseline to Week 12 | -3.8 | Standard Deviation 7.6 | vomiting episodes per week |
| Change From Baseline to Week 12 in Weekly Vomiting Episodes | Relamorelin 100 μg | Change from Baseline to Week 12 | -1.1 | Standard Deviation 13.5 | vomiting episodes per week |
| Change From Baseline to Week 12 in Weekly DGSSD 4-symptom Composite Score (Nausea, Bloating, Early Satiety, Abdominal Pain) | Placebo | Baseline | 21.4 | Standard Deviation 6.7 | score on a scale |
| Change From Baseline to Week 12 in Weekly DGSSD 4-symptom Composite Score (Nausea, Bloating, Early Satiety, Abdominal Pain) | Relamorelin 10 μg | Baseline | 21.8 | Standard Deviation 6.9 | score on a scale |
| Change From Baseline to Week 12 in Weekly DGSSD 4-symptom Composite Score (Nausea, Bloating, Early Satiety, Abdominal Pain) | Relamorelin 30 μg | Baseline | 21.1 | Standard Deviation 6.0 | score on a scale |
| Change From Baseline to Week 12 in Weekly DGSSD 4-symptom Composite Score (Nausea, Bloating, Early Satiety, Abdominal Pain) | Relamorelin 100 μg | Baseline | 22.3 | Standard Deviation 6.2 | score on a scale |
| Change From Baseline to Week 12 in Weekly DGSSD 4-symptom Composite Score (Nausea, Bloating, Early Satiety, Abdominal Pain) | Placebo | Change from Baseline to Week 12 | -5.4 | Standard Deviation 8.1 | score on a scale |
| Change From Baseline to Week 12 in Weekly DGSSD 4-symptom Composite Score (Nausea, Bloating, Early Satiety, Abdominal Pain) | Relamorelin 10 μg | Change from Baseline to Week 12 | -7.7 | Standard Deviation 7.8 | score on a scale |
| Change From Baseline to Week 12 in Weekly DGSSD 4-symptom Composite Score (Nausea, Bloating, Early Satiety, Abdominal Pain) | Relamorelin 30 μg | Change from Baseline to Week 12 | -7.5 | Standard Deviation 7.4 | score on a scale |
| Change From Baseline to Week 12 in Weekly DGSSD 4-symptom Composite Score (Nausea, Bloating, Early Satiety, Abdominal Pain) | Relamorelin 100 μg | Change from Baseline to Week 12 | -8.9 | Standard Deviation 8.3 | score on a scale |
| Change From Baseline to Week 12 for Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-time | Placebo | Baseline | 127.1 | Standard Deviation 36.5 | minutes |
| Change From Baseline to Week 12 for Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-time | Relamorelin 10 μg | Baseline | 126.8 | Standard Deviation 37.6 | minutes |
| Change From Baseline to Week 12 for Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-time | Relamorelin 30 μg | Baseline | 128.6 | Standard Deviation 35.9 | minutes |
| Change From Baseline to Week 12 for Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-time | Relamorelin 100 μg | Baseline | 133.6 | Standard Deviation 35.4 | minutes |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02357420/results